These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 2475275

  • 21. Anaphylatoxin-mediated regulation of human and murine immune responses.
    Morgan EL, Weigle WO, Hugli TE.
    Fed Proc; 1984 Jul; 43(10):2543-7. PubMed ID: 6610569
    [Abstract] [Full Text] [Related]

  • 22. [Atopic dermatitis. II. The status of complement proteins and the pathogenetic role of anaphylatoxins C4a, C3a and C5a].
    Sergeev IuV, Reznikov IuP, Lobanova EV, Pimenova NS.
    Vestn Dermatol Venerol; 1989 Jul; (4):4-7. PubMed ID: 2788339
    [Abstract] [Full Text] [Related]

  • 23. Complement and the damaging effects of cardiopulmonary bypass.
    Westaby S.
    Thorax; 1983 May; 38(5):321-5. PubMed ID: 6603674
    [No Abstract] [Full Text] [Related]

  • 24. Increase of glucose and lactate output and decrease of flow by human anaphylatoxin C3a but not C5a in perfused rat liver.
    Püschel GP, Oppermann M, Muschol W, Götze O, Jungermann K.
    FEBS Lett; 1989 Jan 16; 243(1):83-7. PubMed ID: 2784112
    [Abstract] [Full Text] [Related]

  • 25. Modulation of the immune response by anaphylatoxin in the microenvironment of the interacting cells.
    Weigle WO, Morgan EL, Goodman MG, Chenoweth DE, Hugli TE.
    Fed Proc; 1982 Dec 16; 41(14):3099-103. PubMed ID: 6216123
    [Abstract] [Full Text] [Related]

  • 26. Anaphylatoxins: possible roles in disease.
    Vogt W.
    Complement; 1986 Dec 16; 3(3):177-88. PubMed ID: 3026724
    [Abstract] [Full Text] [Related]

  • 27. Role of the complement anaphylatoxins in inflammation and hypersensitivity reactions in the lung.
    Stimler-Gerard NP.
    Surv Synth Pathol Res; 1985 Dec 16; 4(5-6):423-42. PubMed ID: 3879815
    [No Abstract] [Full Text] [Related]

  • 28. Human C5a des Arg increases vascular permeability.
    José PJ, Forrest MJ, Williams TJ.
    J Immunol; 1981 Dec 16; 127(6):2376-80. PubMed ID: 6170701
    [Abstract] [Full Text] [Related]

  • 29. Anaphylatoxins inhibit C2 production.
    Lappin D, Damerau B, Whaley K.
    Clin Exp Immunol; 1983 Nov 16; 54(2):455-60. PubMed ID: 6317240
    [Abstract] [Full Text] [Related]

  • 30. Mast cells are not required for anaphylatoxin-induced ileal smooth muscle contraction.
    Stimler-Gerard NP, Galli SJ.
    J Immunol; 1987 Mar 15; 138(6):1908-13. PubMed ID: 2434565
    [Abstract] [Full Text] [Related]

  • 31. Anaphylatoxin generation in multisystem organ failure.
    Heideman M, Hugli TE.
    J Trauma; 1984 Dec 15; 24(12):1038-43. PubMed ID: 6334754
    [Abstract] [Full Text] [Related]

  • 32. Anaphylatoxin formation in extracorporeal circuits.
    Chenoweth DE.
    Complement; 1986 Dec 15; 3(3):152-65. PubMed ID: 3492330
    [Abstract] [Full Text] [Related]

  • 33. Functional analysis and quantification of the complement C3 derived anaphylatoxin C3a with a monoclonal antibody.
    Burger R, Bader A, Kirschfink M, Rother U, Schrod L, Wörner I, Zilow G.
    Clin Exp Immunol; 1987 Jun 15; 68(3):703-11. PubMed ID: 3498585
    [Abstract] [Full Text] [Related]

  • 34. Chemotactic effects of the complement-derived peptides C3a, C3ai and C5a (classical anaphylatoxin) on rabbit and guinea-pig polymorphonuclear leukocytes.
    Damerau B, Grünefeld E, Vogt W.
    Naunyn Schmiedebergs Arch Pharmacol; 1978 Nov 15; 305(2):181-4. PubMed ID: 732894
    [Abstract] [Full Text] [Related]

  • 35. Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies.
    Klos A, Ihrig V, Messner M, Grabbe J, Bitter-Suermann D.
    J Immunol Methods; 1988 Jul 22; 111(2):241-52. PubMed ID: 3260926
    [Abstract] [Full Text] [Related]

  • 36. The extracellular neutral cysteine proteinase of Entamoeba histolytica degrades anaphylatoxins C3a and C5a.
    Reed SL, Ember JA, Herdman DS, DiScipio RG, Hugli TE, Gigli I.
    J Immunol; 1995 Jul 01; 155(1):266-74. PubMed ID: 7602103
    [Abstract] [Full Text] [Related]

  • 37. Minor role of the C3a receptor in systemic anaphylaxis in the guinea pig.
    Regal JF, Klos A.
    Immunopharmacology; 2000 Jan 01; 46(1):15-28. PubMed ID: 10665776
    [Abstract] [Full Text] [Related]

  • 38. The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a, and C5a.
    Hugli TE.
    Crit Rev Immunol; 1981 Feb 01; 1(4):321-66. PubMed ID: 7037298
    [No Abstract] [Full Text] [Related]

  • 39. Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells.
    el-Lati SG, Dahinden CA, Church MK.
    J Invest Dermatol; 1994 May 01; 102(5):803-6. PubMed ID: 7513741
    [Abstract] [Full Text] [Related]

  • 40. The ischaemic leg as a source of complement activation.
    Bengtson A, Holmberg P, Heideman M.
    Br J Surg; 1987 Aug 01; 74(8):697-700. PubMed ID: 3498527
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.